Cancer treatment and research communicationsHumansTamoxifenBreast NeoplasmsDrug ResistanceNeoplasm
Uncovering the transcriptomic basis of endoxifen resistance in ER+ breast cancer cells: Insights from bioinformatics analysis.
H Lawrence Remmel, Sandra S Hammer, John R Hawse, Anastasia Shneyderman, Alexander Veviorskiy, Khadija M Alawi, Mikhail Korzinkin, Alex Zhavoronkov, Steven C Quay
Published: 202510.1016/j.ctarc.2025.101044
Abstract
Estrogen receptor alpha-positive (ER+) breast cancer remains a major clinical challenge due to the development of de novo and acquired resistance to endocrine therapy. (Z)-endoxifen (hereafter endoxifen), the most abundant active tamoxifen metabolite…
Preview only. Read the full abstract at the source